Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group

Cattran, 2009, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification, Kidney Int, 76, 534, 10.1038/ki.2009.243

Coppo, 2010, The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults, Kidney Int, 77, 921, 10.1038/ki.2010.43

Kim, 2014, Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schönlein purpura nephritis in adults, Mod Pathol, 27, 972, 10.1038/modpathol.2013.222

Bellur, 2011, Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort, Nephrol Dial Transplant, 26, 2533, 10.1093/ndt/gfq812

Joh K, Hashiguchi A, Okonogi H, et al. Histological evaluation on IgA nephropathy in 233 Japanese adult patients: retrospective analysis (abstract; poster no. 12). Oral and poster presented at: the World Congress of Nephrology 2009 Satellite Symposium on IgA Nephropathy. May 22–26, 2009; Milan Italy.

Katafuchi, 2011, Validation study of oxford classification of IgA nephropathy: The significance of extracapillary proliferation, Clin J Am Soc Nephrol, 6, 2806, 10.2215/CJN.02890311

Herzenberg, 2011, Validation of the Oxford classification of IgA nephropathy, Kidney Int, 80, 310, 10.1038/ki.2011.126

El Karoui, 2012, A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy, J Am Soc Nephrol, 23, 137, 10.1681/ASN.2010111130

Shi, 2011, Pathologic predictors of renal outcome and therapeutic efficacy in IgA nephropathy: validation of the oxford classification, Clin J Am Soc Nephrol, 6, 2175, 10.2215/CJN.11521210

Alamartine, 2011, The use of the Oxford classification of IgA nephropathy to predict renal survival, Clin J Am Soc Nephrol, 6, 2384, 10.2215/CJN.01170211

Yau, 2011, The Oxford Classification of IgA Nephropathy: a retrospective analysis, Am J Nephrol, 34, 435, 10.1159/000332223

Edström Halling, 2012, Predictors of outcome in paediatric IgA nephropathy with regard to clinical and histopathological variables (Oxford classification), Nephrol Dial Transplant, 27, 715, 10.1093/ndt/gfr339

Shima, 2012, Validity of the Oxford classification of IgA nephropathy in children, Pediatr Nephrol, 27, 783, 10.1007/s00467-011-2061-0

Kataoka, 2012, Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters, Clin Exp Nephrol, 16, 706, 10.1007/s10157-012-0613-7

Le, 2012, Validation of the Oxford Classification of IgA Nephropathy for pediatric patients from China, BMC Nephrol, 13, 158, 10.1186/1471-2369-13-158

Lee, 2012, Validation of the Oxford Classification of IgA Nephropathy: a single-center study in Korean adults, Korean J Intern Med, 27, 293, 10.3904/kjim.2012.27.3.293

Zeng, 2012, A multicenter application and evaluation of the Oxford Classification of IgA Nephropathy in adult Chinese patients, Am J Kidney Dis, 60, 812, 10.1053/j.ajkd.2012.06.011

Kang, 2012, The Oxford Classification as a predictor of prognosis in patients with IgA nephropathy, Nephrol Dial Transplant, 27, 252, 10.1093/ndt/gfr295

Moriyama, 2012, Severity of nephrotic IgA nephropathy according to the Oxford Classification, Int Urol Nephrol, 44, 1177, 10.1007/s11255-011-0109-5

Gutierrez, 2012, Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria, J Am Soc Nephrol, 23, 1753, 10.1681/ASN.2012010063

Lv, 2013, Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis, Am J Kidney Dis, 62, 891, 10.1053/j.ajkd.2013.04.021

Nasri, 2012, Oxford-MEST classification in IgA nephropathy patients: a report from Iran, J Nephropathol, 1, 31, 10.5812/jnp.7

Coppo, 2014, Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments, Kidney Int, 86, 828, 10.1038/ki.2014.63

Espinosa, 2014, Association of C4d deposition with clinical outcomes in IgA nephropathy, Clin J Am Soc Nephrol, 9, 897, 10.2215/CJN.09710913

Moriyama, 2014, Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan, PLoS One, 9, e91756, 10.1371/journal.pone.0091756

Park, 2014, Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy, Hum Pathol, 45, 236, 10.1016/j.humpath.2013.08.019

Chakera, 2016, Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression, J Nephrol, 29, 367

Hou JH, Le WB, Chen N, et al. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial [e-pub ahead of print]. Am J Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2016.11.02. Accessed March 15, 2017.

Shen, 2015, Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation, J Nephrol, 28, 441

Bellur, 2017, Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy, Kidney Int, 91, 235, 10.1016/j.kint.2016.09.029

Haas M, Verhave JC, Liu ZH, et al. A Multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol., in press.

Coppo, 2017, Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort, Pediatr Nephrol, 32, 139, 10.1007/s00467-016-3469-3

Bartosik, 2001, Predicting progression in IgA nephropathy, Am J Kidney Dis, 38, 728, 10.1053/ajkd.2001.27689

Barbour, 2016, Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia. The MEST score provides earlier risk prediction in IgA nephropathy, Kidney Int, 89, 167, 10.1038/ki.2015.322

Barbour SJ, Reich H, Suzuki Y, et al. A global platform for prediction modelling in 4915 patients with IgA nephropathy from Asia, Europe and the Americas (Abstract P0626). Presented at: ASN Annual Meeting, 2016, Chicago, IL.

Coppo R. Biomarkers and targeted new therapies for IgA nephropathy [e-pub ahead of print]. Pediatr Nephrol. http://dx.doi.org/10.1007/s00467-016-3390-9. Accessed March 15, 2017.

Berthoux, 2012, Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy, J Am Soc Nephrol, 23, 1579, 10.1681/ASN.2012010053

Wu, 2012, Characterization and quantification of proliferating cell patterns in endocapillary proliferation, Nephrol Dial Transplant, 27, 3234, 10.1093/ndt/gfr797